Skip to main
Genetic science research
George Mason University
News

Liotta Conducting Virologic Analysis Of SARS-CoV-2

Elizabeth Grisham
Lance Liotta, PhD

Lance Liotta, Co-Director, Center for Applied Proteomics and Molecular Medicine (CAPMM), is conducting virologic analyses of SARS-CoV-2 on non-infectious/pre-inactivated clinical samples using FDA-cleared (Emergency Use Authorized) commercial PCR platforms. 

As part of this work, CAPMM researchers are providing space and necessary laboratory information management systems (LIMS) in their College of American Pathologists/Clinical Laboratory Improvement Amendments (CAP/CLIA) facility for the project tasks.  

CAPMM researchers are also providing time and expertise for maintaining CAP/CLIA paperwork and associated regulatory requirements. 

Liotta received $16,283 from TruGenomix Health, LLC, for this project. Funding began in July 2020 and will end in late June 2021. 

* The programs and services offered by George Mason University are open to all who seek them. George Mason does not discriminate on the basis of race, color, religion, ethnic national origin (including shared ancestry and/or ethnic characteristics), sex, disability, military status (including veteran status), sexual orientation, gender identity, gender expression, age, marital status, pregnancy status, genetic information, or any other characteristic protected by law. After an initial review of its policies and practices, the university affirms its commitment to meet all federal mandates as articulated in federal law, as well as recent executive orders and federal agency directives.